COVID-19

Britain approves Pfizer’s antiviral COVID-19 pill

Reuters
Britain approves Pfizer’s antiviral COVID-19 pill

ANTI-COVID PILL. Paxlovid, a Pfizer's coronavirus disease pill, is manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021.

Pfizer/Handout via REUTERS

Pfizer says Paxlovid shows near 90% efficacy in preventing hospitalizations and deaths in high-risk patients

Britain has approved Pfizer’s COVID-19 pill for patients over the age of 18 years who have mild to moderate infection and are at high risk of their illness worsening.

The approval comes as the country scrambles to build its defenses amid a record hit a daily record of new COVID-19 cases on Thursday, December 30, government data showed surge in COVID-19 cases.

Based on data, the pill, Paxlovid, is most effective when taken during the early stages of COVID-19, Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday, December 31, recommending that the drug be used within five days of the onset of symptoms.

Pfizer this month said Paxlovid showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.

“We now have a further antiviral medicine for the treatment of COVID-19 that can be taken by mouth rather than administered intravenously. This means it can be administered outside a hospital setting,” MHRA chief June Raine said in a statement. – Rappler.com

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.